Upcoming events – Rare disease data due from Chemocentryx and Sanofi
Chemocentryx and Sanofi are looking to target the complement pathway in ANCA-associated vasculitis and cold agglutinin disease respectively, with phase III data due in…
Small and mid-cap share price gains make up for majors
Deals were a major driver of mid-cap share movement in the first quarter, but pipeline progress and misfires played their parts too.
